Bill Taranto

We're starting to see now as we move into the end of this year and next year, markets are opening up.

As you said, the growth rounds, we're seeing lots of capital coming back and we're seeing lots of capital coming back in the startup.

The A and B rounds are still struggling a little bit, but that's I still think a byproduct of the overpricing.

But we're seeing a lot of consolidation.

The private equity firms have a lot of money and they see the value of what we were doing in consolidating all these assets.

We're seeing a lot of discussions, outreach, and a lot of just consolidation and holding of assets.

And the public markets are starting to open up a little bit.

So if you want to IPO, I think that will come back a little bit.

But I've seen a bigger play in the consolidation market of these platforms because people see that if you can build that scale,

That's what then drives the ultimate value of the company and the revenue, because then you get more clients, you know, and certainly if you're, if you're focusing on pharma as a client, you know, you as an end client, that, that group wants scale.

in order to work with companies.

So I think some good lessons learned, but there's certainly nothing wrong with the market key recalibration and we needed it in the digital market and it happened.

And I think some good has come out of it.

I think the biggest area – it's funny.

The most interesting area where pharma is focusing is that AI and ML and drug discovery.

And the reason that's hard to scale is all these companies do it differently.

They all have their secret sauce and just do it slightly differently.

And it's sort of hard to think about how would you merge those together because they all do it slightly different.

The other thing that makes that market a little different, it's the one market where if –

The AI and ML drug company develops a target.